NCT00864487已完成1 期
A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Pharmacokinetics (plasma blood concentrations)
研究概览
简要总结
The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Neratinib alone
干预措施: Neratinib (Drug)
2
Experimental
Neratinib plus rifampin
干预措施: Neratinib (Drug)
结局指标
主要结局
Pharmacokinetics (plasma blood concentrations)
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Effect of Rifampin on Bosutinib When Both Are Given to Healthy PeopleHealthyNCT00725426Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
2 期
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularNCT01915602Bayer14
已完成
1 期
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid TumorsAdvanced Solid NeoplasmNCT03486314Millennium Pharmaceuticals, Inc.20
撤回
1 期
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199Non-Hodgkin's LymphomaNCT01969682AbbVie
进行中（未招募）
2 期
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT05287113Incyte Biosciences International Sàrl176